Business
Grant for NHS point-of-care test
Grant for NHS point-of-care test.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 9237R Genedrive PLC 20 June 2018 \n\nFor release: 20 June 2018\n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \ngenedrive plc (\"genedrive\" or the \"Company\")\n \nGrant to develop and implement a point-of-care test in the NHS to avoid antibiotic-related hearing loss in newborn children\n \n Funded through UK NHS National Institute for Health Research\ngenedrive plc, the near patient molecular diagnostics company, today announces its receipt of a multi-partner grant award from the UK National Institute for Health Research's Invention for Innovation programme, for the development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children. \nDue to an identified genetic predisposition, certain individuals develop irreversible hearing loss when exposed to gentamicin, an antibiotic used to treat several types of bacterial infections. In the UK, approximately 90,000 babies per year are treated with gentamicin on intensive care units. Antibiotic treatment should start within the first hour after admission, but current lab-based genetic tests are not able to return actionable results within that timeframe. A Genedrive® test is targeted to allow genetic results to be available within an hour, allowing alternative antibiotics to be used and thus avoiding the potential life changing adverse reaction to gentamicin.\nThe project is expected to commence immediately, with an expected development phase of one year followed by a trial implementation phase in selected NHS hospitals in year two. The Company will then target the release of a Genedrive® test within the NHS and more broadly. This project represents an important landmark for the Company's Genedrive® platform as it is the first potential application outside of the low and middle income markets targeted with current HCV and mTB programmes. genedrive expects to account for its £550,000 share of the project funding as income which will be matched to costs incurred over the two year project. ...